Probing the relevance of 3D cancer models in nanomedicine research

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 95-106

  Leong, David T ^a   Ng, Kee Woei ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

3D culture; Cell nanoparticle interaction; Nanoparticles; Nanotheranostics; Nanotherapeutics; Nanotoxicology; Spheroid

Indexed keywords

CELL CULTURE; CELLS; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

3-D CULTURES; NANOPARTICLE INTERACTION; NANOTHERANOSTICS; NANOTHERAPEUTICS; NANOTOXICOLOGY; SPHEROID;

DISEASES;

ANTINEOPLASTIC AGENT; MULTI WALLED NANOTUBE;

CANCER CELL; CANCER MODEL; CANCER RESEARCH; CANCER THERAPY; CELL CULTURE; CELL HETEROGENEITY; CHEMICAL ANALYSIS; CLINICAL RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOMEDICINE; PHENOTYPE; PROTEIN SECRETION; REVIEW; ANIMAL; BIOLOGICAL MODEL; CULTURE TECHNIQUE; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; HUMANS; MODELS, BIOLOGICAL; NANOMEDICINE; NEOPLASMS;

EID: 84919668228     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.06.007     Document Type: Review

References (158)

1. Smalley K.S., Lioni M., Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell. Dev. Biol. Anim. 2006, 42:242-247.
2. Abbott A. Cell culture: biology's new dimension. Nature 2003, 424:870-872.
3. Harunaga J.S., Yamada K.M. Cell-matrix adhesions in 3D. Matrix Biol. 2011, 30:363-368.
4. HTStec 3D Cell Culture Trends 2011 2011, (Cambridge, UK).
5. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat. Mater. 2010, 9:90-93.
6. Weaver V.M., Petersen O.W., Wang F., Larabell C.A., Briand P., Damsky C., Bissell M.J. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 1997, 137:231-245.
7. Bissell M.J., Rizki A., Mian I.S. Tissue architecture: the ultimate regulator of breast epithelial function. Curr. Opin. Cell Biol. 2003, 15:753-762.
8. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
9. Yu Y., Zhang Q., Xie J., Lee J.Y. Engineering the architectural diversity of heterogeneous metallic nanocrystals. Nat. Commun. 2013, 4:1454.
10. 25 nanoclusters with atomic precision. Angew. Chem. Int. Ed. Engl. 2014, 53:4623-4627.
11. Tan G.R., Feng S.S., Leong D.T. The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. Biomaterials 2014, 35:3044-3051.
12. Tay C.Y., Fang W., Setyawati M.I., Sum C.P., Xie J., Ng K.W., Chen X., Hong C.H.L., Leong D.T. Reciprocal response of human oral epithelial cells to internalized silica nanoparticles. Part. Part. Syst. Charact. 2013, 30:784-793.
13. Zhang X.D., Chen J., Luo Z., Wu D., Shen X., Song S.S., Sun Y.M., Liu P.X., Zhao J., Huo S., Fan S., Fan F., Liang X.J., Xie J. Enhanced tumor accumulation of sub-2nm gold nanoclusters for cancer radiation therapy. Adv. Healthc. Mater. 2014, 3:133-141.
14. Muthu M.S., Leong D.T., Mei L., Feng S.S. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4:660-677.
15. 10-12 nanomolecules for high tumor specificity and cancer radiotherapy. Adv. Mater. 2014, (in press). 10.1002/adma.201400866.
16. 18 nanocluster. J. Am. Chem. Soc. 2014, 136:1246-1249.
17. Zhao Y., Howe J.L., Yu Z., Leong D.T., Chu J.J., Loo J.S., Ng K.W. Exposure to titanium dioxide nanoparticles induces autophagy in primary human keratinocytes. Small 2013, 9:387-392.
18. Tay C.Y., Cai P.Q., Setyawati M.I., Fang W., Tan L.P., Hong C.H.L., Chen X., Leong D.T. Nanoparticles strengthen intracellular tension and retard cellular migration. Nano Lett. 2013, 14:83-88.
19. Setyawati M.I., Khoo P.K.S., Eng B.H., Xiong S., Zhao X., Das G.K., Tan T.T.-Y., Loo J.S.C., Leong D.T., Ng K.W. Cytotoxic and genotoxic characterization of titanium dioxide, gadolinium oxide, and poly(lactic-co-glycolic acid) nanoparticles in human fibroblasts. J. Biomed. Mater. Res. A 2013, 101A:633-640.
20. Zhang W., Ji Y., Wu X., Xu H. Trafficking of gold nanorods in breast cancer cells: uptake, lysosome maturation, and elimination. ACS Appl. Mater. Interfaces 2013, 5:9856-9865.
21. Setyawati M.I., Tay C.Y., Leong D.T. Exploiting cancer's antioxidative weakness through p53 with nanotoxicology. Nanomedicine (Lond. Engl.) 2014, 9:369-371.
22. Mustafa T., Zhang Y., Watanabe F., Karmakar A., Asar M.P., Little R., Hudson M.K., Xu Y., Biris A.S. Iron oxide nanoparticle-based radio-frequency thermotherapy for human breast adenocarcinoma cancer cells. Biomater. Sci. 2013, 1:870-880.
23. Yuan X., Setyawati M., Leong D., Xie J. Ultrasmall Ag+-rich nanoclusters as highly efficient nanoreservoirs for bacterial killing. Nano Res. 2014, 7:301-307.
24. Giovanni M., Tay C.Y., Inggrid Setyawati M., Xie J., Ong C.N., Fan R., Yue J., Zhang L., Tai Leong D. Toxicity profiling of water contextual zinc oxide, silver, and titanium dioxide nanoparticles in human oral and gastrointestinal cell systems. Environ. Toxicol. 2014, (in press). 10.1002/tox.22015.
25. Setyawati M.I., Tay C.Y., Leong D.T. The gap between endothelial cells: key to the quick escape of nanomaterials?. Nanomedicine 2014, (in press). 10.2217/NNM.14.104.
26. Yuan X., Setyawati M.I., Tan A.S., Ong C.N., Leong D.T., Xie J. Highly luminescent silver nanoclusters with tunable emissions: cyclic reduction-decomposition synthesis and antimicrobial properties. NPG Asia Mater. 2013, 5:e39.
27. Ng K.W., Khoo S.P., Heng B.C., Setyawati M.I., Tan E.C., Zhao X., Xiong S., Fang W., Leong D.T., Loo J.S. The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles. Biomaterials 2011, 32:8218-8225.
28. Setyawati M.I., Tay C.Y., Leong D.T. Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway. Biomaterials 2013, 34:10133-10142.
29. Setyawati M.I., Fang W., Chia S.L., Leong D.T. Nanotoxicology of common metal oxide based nanomaterials: their ROS-y and non-ROS-y consequences. Asia Pac. J. Chem. Eng. 2013, 8:205-217.
30. Tay C.Y., Leong D.T. Inorganic nanoparticles as tubulin binding agents for cancer therapy. Nanomedicine 2014, (in press). 10.2217/NNM.14.105.
31. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013, 9:1-14.
32. Prabhu P., Patravale V. The upcoming field of theranostic nanomedicine: an overview. J. Biomed. Nanotechnol. 2012, 8:859-882.
33. Tong R., Kohane D.S. Shedding light on nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2012, 4:638-662.
34. Zhang X.Q., Xu X., Bertrand N., Pridgen E., Swami A., Farokhzad O.C. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv. Drug Deliv. Rev. 2012, 64:1363-1384.
35. Chow E.K., Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci. Transl. Med. 2013, 5. (216rv214).
36. Chithrani B.D., Stewart J., Allen C., Jaffray D.A. Intracellular uptake, transport, and processing of nanostructures in cancer cells. Nanomed. Nanotechnol. biol. Med. 2009, 5:118-127.
37. Peckys D.B., de Jonge N. Visualizing gold nanoparticle uptake in live cells with liquid scanning transmission electron microscopy. Nano Lett. 2011, 11:1733-1738.
38. Cheng L.C., Jiang X., Wang J., Chen C., Liu R.S. Nano-bio effects: interaction of nanomaterials with cells. Nanoscale 2013, 5:3547-3569.
39. Tay C.Y., Yong Y., Setyawati M.I., Xie J., Leong D.T. Presentation matters: identity of gold nanoclusters capping agent governs intracellular uptake and cell metabolism. Nano Res. 2014, (in press). 10.1007/s12274-014-0441-z.
40. Tay C.Y., Fang W., Setyawati M.I., Chia S.L., Tan K.S., Hong C.H.L., Leong D.T. Nano-hydroxyapatite and nano-titanium dioxide exhibit different subcellular distribution and apoptotic profile in human oral epithelium. ACS Appl. Mater. Interfaces 2014, 6:6248-6256.
41. Wu Y.L., Putcha N., Ng K.W., Leong D.T., Lim C.T., Loo S.C., Chen X. Biophysical responses upon the interaction of nanomaterials with cellular interfaces. Acc. Chem. Res. 2013, 46:782-791.
42. Setyawati M.I., Yuan X., Xie J., Leong D.T. The influence of lysosomal stability of silver nanomaterials on their toxicity to human cells. Biomaterials 2014, (in press). 10.1016/j.biomaterials.2014.05.007.
43. Huang D.Y., Hou Y.L., Yang S.M., Wang R.G. Advances in nanomedicine for head and neck cancer. Front. Biosci. (Landmark Ed.) 2014, 19:783-788.
44. Del Burgo L.S., Hernandez R.M., Orive G., Pedraz J.L. Nanotherapeutic approaches for brain cancer management. Nanomedicine: Nanotechnology, Biology and Medicine 2014, 10(5):905-919.
45. Sanna V., Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine 2012, 8(Suppl. 1):S31-S36.
46. Chen J., Shao R., Zhang X.D., Chen C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int. J. Nanomedicine 2013, 8:2677-2688.
47. Sykes P.D., Neoptolemos J.P., Costello E., Halloran C.M. Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer. Expert Rev. Gastroenterol. Hepatol. 2012, 6:343-356.
48. Thorley A.J., Tetley T.D. New perspectives in nanomedicine. Pharmacol. Ther. 2013, 140(2):176-185.
49. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
50. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
51. Setyawati M.I., Tay C.Y., Chia S.L., Goh S.L., Fang W., Neo M.J., Chong H.C., Tan S.M., Loo S.C., Ng K.W., Xie J.P., Ong C.N., Tan N.S., Leong D.T. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. Nat. Commun. 2013, 4:1673.
52. Glazer E.S., Zhu C., Hamir A.N., Borne A., Thompson C.S., Curley S.A. Biodistribution and acute toxicity of naked gold nanoparticles in a rabbit hepatic tumor model. Nanotoxicology 2011, 5:459-468.
53. Borm P.J.A., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3:11.
54. Donaldson K., Stone V., Tran C.L., Kreyling W., Borm P.J. Nanotoxicol. Occup. Environ. Med. 2004, 61:727-728.
55. Kathawala M.H., Xiong S., Richards M., Ng K.W., George S., Loo S.C.J. Emerging in vitro models for safety screening of high-volume production nanomaterials under environmentally relevant exposure conditions. Small 2013, 9:1504-1520.
56. Gonzalez L., Thomassen L.C., Plas G., Rabolli V., Napierska D., Decordier I., Roelants M., Hoet P.H., Kirschhock C.E., Martens J.A., Lison D., Kirsch-Volders M. Exploring the aneugenic and clastogenic potential in the nanosize range: A549 human lung carcinoma cells and amorphous monodisperse silica nanoparticles as models. Nanotoxicology 2010, 4:382-395.
57. Srivastava R.K., Pant A.B., Kashyap M.P., Kumar V., Lohani M., Jonas L., Rahman Q. Multi-walled carbon nanotubes induce oxidative stress and apoptosis in human lung cancer cell line-A549. Nanotoxicology 2011, 5:195-207.
58. Paino I.M., Marangoni V.S., de Oliveira Rde C., Antunes L.M., Zucolotto V. Cyto and genotoxicity of gold nanoparticles in human hepatocellular carcinoma and peripheral blood mononuclear cells. Toxicol. Lett. 2012, 215:119-125.
59. Petkovic J., Zegura B., Stevanovic M., Drnovsek N., Uskokovic D., Novak S., Filipic M. DNA damage and alterations in expression of DNA damage responsive genes induced by TiO2 nanoparticles in human hepatoma HepG2 cells. Nanotoxicology 2011, 5:341-353.
60. Pelka J., Gehrke H., Rechel A., Kappes M., Hennrich F., Hartinger C.G., Marko D. DNA damaging properties of single walled carbon nanotubes in human colon carcinoma cells. Nanotoxicology 2013, 7:2-20.
61. Sanna V., Pala N., Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int. J. Nanomedicine 2014, 9:467-483.
62. Dai W., Yang T., Wang Y., Wang X., Wang J., Zhang X., Zhang Q. Peptide PHSCNK as an integrin alpha5beta1 antagonist targets stealth liposomes to integrin-overexpressing melanoma. Nanomedicine 2012, 8:1152-1161.
63. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
64. Palekar-Shanbhag P., Jog S.V., Chogale M.M., Gaikwad S.S. Theranostics for cancer therapy. Curr. Drug Deliv. 2013, 10:357-362.
65. Svenson S. Theranostics: are we there yet?. Mol. Pharm. 2013, 10:848-856.
66. Diou O., Tsapis N., Fattal E. Targeted nanotheranostics for personalized cancer therapy. Expert Opin. Drug Deliv. 2012, 9:1475-1487.
67. Kim J.W., Galanzha E.I., Zaharoff D.A., Griffin R.J., Zharov V.P. Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol. Pharm. 2013, 10:813-830.
68. Kim T.H., Lee S., Chen X. Nanotheranostics for personalized medicine. Expert. Rev. Mol. Diagn. 2013, 13:257-269.
69. Wang L.S., Chuang M.C., Ho J.A. Nanotheranostics -a review of recent publications. Int. J. Nanomedicine 2012, 7:4679-4695.
70. Vannucci L., Falvo E., Fornara M., Di Micco P., Benada O., Krizan J., Svoboda J., Hulikova-Capkova K., Morea V., Boffi A., Ceci P. Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int. J. Nanomedicine 2012, 7:1489-1509.
71. Han N., Yang Y.Y., Wang S., Zheng S., Fan W. Polymer-based cancer nanotheranostics: retrospectives of multi-functionalities and pharmacokinetics. Curr. Drug Metab. 2013, 14:661-674.
72. Ahmed N., Fessi H., Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov. Today 2012, 17:928-934.
73. Singh A., Sahoo S.K. Magnetic nanoparticles: a novel platform for cancer theranostics. Drug Discov. Today 2014, 19:474-481.
74. Gustafson T.P., Lim Y.H., Flores J.A., Heo G.S., Zhang F., Zhang S., Samarajeewa S., Raymond J.E., Wooley K.L. Holistic assessment of covalently labeled core-shell polymeric nanoparticles with fluorescent contrast agents for theranostic applications. Langmuir 2014, 30:631-641.
75. Ng K.W., Leong D.T.W., Hutmacher D.W. The challenge to measure cell proliferation in two and three dimensions. Tissue Eng. 2005, 11:182-191.
76. Ho V.H., Guo W.M., Huang C.L., Ho S.F., Chaw S.Y., Tan E.Y., Ng K.W., Loo J.S. Manipulating magnetic 3D spheroids in hanging drops for applications in tissue engineering and drug screening. Adv. Healthc. Mater. 2013, 2:1430-1434.
77. Pampaloni F., Reynaud E.G., Stelzer E.H.K. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 2007, 8:839-845.
78. Lee J., Cuddihy M.J., Kotov N.A. Three-dimensional cell culture matrices: state of the art. Tissue Eng. B Rev. 2008, 14:61-86.
79. Tay C.Y., Pal M., Yu H.Y., Leong W.S., Tan N.S., Ng K.W., Venkatraman S., Boey F., Leong D.T., Tan L.P. Bio-inspired micropatterned platform to steer stem cell differentiation. Small 2011, 7:1416-1421.
80. Tay C.Y., Yu H.Y., Pal M., Leong W.S., Tan N.S., Ng K.W., Leong D.T., Tan L.P. Micropatterned matrix directs differentiation of human mesenchymal stem cells towards myocardial lineage. Exp. Cell Res. 2010, 316:1159-1168.
81. McCaffrey L.M., Macara I.G. Epithelial organization, cell polarity and tumorigenesis. Trends Cell Biol. 2011, 21:727-735.
82. O'Brien L.E., Zegers M.M., Mostov K.E. Opinion: building epithelial architecture: insights from three-dimensional culture models. Nat. Rev. Mol. Cell Biol. 2002, 3:531-537.
83. Hua W., Sheff D., Toomre D., Mellman I. Vectorial insertion of apical and basolateral membrane proteins in polarized epithelial cells revealed by quantitative 3D live cell imaging. J. Cell Biol. 2006, 172:1035-1044.
84. Bryant D.M., Mostov K.E. From cells to organs: building polarized tissue. Nat. Rev. Mol. Cell Biol. 2008, 9:887-901.
85. Lodish H., Berk A., Zipursky S. Actin and myosin in nonmuscle cells. Molecular Cell Biology, New York 2000, W.H. Freeman (Ed.).
86. Chang T.T., Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng. A 2009, 15:559-567.
87. Zaman M.H., Trapani L.M., Sieminski A.L., Mackellar D., Gong H., Kamm R.D., Wells A., Lauffenburger D.A., Matsudaira P. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10889-10894.
88. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science (New York, N.Y.) 2001, 294:1708-1712.
89. Huh D., Hamilton G.A., Ingber D.E. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011, 21:745-754.
90. Zhang F., Xu R., Zhao M.J. QSG-7701 human hepatocytes form polarized acini in three-dimensional culture. J. Cell. Biochem. 2010, 110:1175-1186.
91. Discher D.E., Janmey P., Wang Y.L. Tissue cells feel and respond to the stiffness of their substrate. Science (New York, N.Y.) 2005, 310:1139-1143.
92. Ren K., Crouzier T., Roy C., Picart C. Polyelectrolyte multilayer films of controlled stiffness modulate myoblast cells differentiation. Adv. Funct. Mater. 2008, 18:1378-1389.
93. Park J.S., Chu J.S., Tsou A.D., Diop R., Tang Z., Wang A., Li S. The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-beta. Biomaterials 2011, 32:3921-3930.
94. Daley W.P., Peters S.B., Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J. Cell Sci. 2008, 121:255-264.
95. Zhang S., Gelain F., Zhao X. Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures. Semin. Cancer Biol. 2005, 15:413-420.
96. Nichols J.E., Cortiella J., Lee J., Niles J.A., Cuddihy M., Wang S., Bielitzki J., Cantu A., Mlcak R., Valdivia E., Yancy R., McClure M.L., Kotov N.A. In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. Biomaterials 2009, 30:1071-1079.
97. Walker T.M., Woodrooffe A.J. Cytochrome P450 activity in control and induced long-term cultures of rat hepatocyte spheroids. Toxicol. In Vitro 2001, 15:713-719.
98. Leong D.T., Khor W.M., Chew F.T., Lim T.C., Hutmacher D.W. Characterization of osteogenically induced adipose tissue-derived precursor cells in 2-dimensional and 3-dimensional environments. Cells Tissues Organs 2006, 182:1-11.
99. Leong D.T., Abraham M.C., Rath S.N., Lim T.C., Chew F.T., Hutmacher D.W. Investigating the effects of preinduction on human adipose-derived precursor cells in an athymic rat model. Differentiation 2006, 74:519-529.
100. Leong D.T., Nah W.K., Gupta A., Hutmacher D.W., Woodruff M.A. The osteogenic differentiation of adipose tissue-derived precursor cells in a 3D scaffold/matrix environment. Curr. Drug Discov. Technol. 2008, 5:319-327.
101. Khaoustov V.I., Darlington G.J., Soriano H.E., Krishnan B., Risin D., Pellis N.R., Yoffe B. Induction of three-dimensional assembly of human liver cells by simulated microgravity. In Vitro Cell. Dev. Biol. Anim. 1999, 35:501-509.
102. Montesano R., Schaller G., Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 1991, 66:697-711.
103. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 2005, 167:475-488.
104. Wang R., Xu J., Juliette L., Castilleja A., Love J., Sung S.Y., Zhau H.E., Goodwin T.J., Chung L.W. Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. Semin. Cancer Biol. 2005, 15:353-364.
105. Leong D.T., Abraham M.C., Gupta A., Lim T.C., Chew F.T., Hutmacher D.W. ATF5, a possible regulator of osteogenic differentiation in human adipose-derived stem cells. J. Cell. Biochem. 2012, 113:2744-2753.
106. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
107. Hofmann A., Ritz U., Verrier S., Eglin D., Alini M., Fuchs S., Kirkpatrick C.J., Rommens P.M. The effect of human osteoblasts on proliferation and neo-vessel formation of human umbilical vein endothelial cells in a long-term 3D co-culture on polyurethane scaffolds. Biomaterials 2008, 29:4217-4226.
108. Chung S., Sudo R., Mack P.J., Wan C.R., Vickerman V., Kamm R.D. Cell migration into scaffolds under co-culture conditions in a microfluidic platform. Lab Chip 2009, 9:269-275.
109. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
110. Kim J.B. Three-dimensional tissue culture models in cancer biology. Semin. Cancer Biol. 2005, 15:365-377.
111. Radisic M., Malda J., Epping E., Geng W., Langer R., Vunjak-Novakovic G. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. Biotechnol. Bioeng. 2006, 93:332-343.
112. Mazzoleni G., Di Lorenzo D., Steimberg N. Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?. Genes Nutr. 2009, 4:13-22.
113. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
114. Astashkina A., Mann B., Grainger D.W. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Ther. 2012, 134:82-106.
115. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 2004, 9:273-285.
116. Rangarajan A., Hong S.J., Gifford A., Weinberg R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6:171-183.
117. Vorsmann H., Groeber F., Walles H., Busch S., Beissert S., Walczak H., Kulms D. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell death Dis. 2013, 4:e719.
118. Marrero B., Heller R. The use of an in vitro 3D melanoma model to predict in vivo plasmid transfection using electroporation. Biomaterials 2012, 33:3036-3046.
119. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
120. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
121. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 2007, 4:359-365.
122. Yoshii Y., Waki A., Yoshida K., Kakezuka A., Kobayashi M., Namiki H., Kuroda Y., Kiyono Y., Yoshii H., Furukawa T., Asai T., Okazawa H., Gelovani J.G., Fujibayashi Y. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011, 32:6052-6058.
123. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12:853-859.
124. Dolznig H., Rupp C., Puri C., Haslinger C., Schweifer N., Wieser E., Kerjaschki D., Garin-Chesa P. Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am. J. Pathol. 2011, 179:487-501.
125. Yamamoto H., Soh J.W., Monden T., Klein M.G., Zhang L.M., Shirin H., Arber N., Tomita N., Schieren I., Stein C.A., Weinstein I.B. Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin. Cancer Res. 1999, 5:1805-1815.
126. Sutherland R.M., Sordat B., Bamat J., Gabbert H., Bourrat B., Mueller-Klieser W. Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res. 1986, 46:5320-5329.
127. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 2002, 94:883-893.
128. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., Sprick M.R., Kemper K., Richel D.J., Stassi G., Medema J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
129. Holzapfel B.M., Wagner F., Loessner D., Holzapfel N.P., Thibaudeau L., Crawford R., Ling M.T., Clements J.A., Russell P.J., Hutmacher D.W. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014, 35:4108-4115.
130. Thibaudeau L., Taubenberger A.V., Holzapfel B.M., Quent V.M., Fuehrmann T., Hesami P., Brown T.D., Dalton P.D., Power C.A., Hollier B.G., Hutmacher D.W. A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Dis. Model. Mech. 2014, 7:299-309.
131. Taubenberger A.V., Quent V.M., Thibaudeau L., Clements J.A., Hutmacher D.W. Delineating breast cancer cell interactions with engineered bone microenvironments. J. Bone Miner. Res. 2013, 28:1399-1411.
132. Thibaudeau L., Quent V.M., Holzapfel B.M., Taubenberger A.V., Straub M., Hutmacher D.W. Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies. Cancer Metastasis Rev. 2014, (in press).
133. Mitra M., Mohanty C., Harilal A., Maheswari U.K., Sahoo S.K., Krishnakumar S. A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol. Vis. 2012, 18:1361-1378.
134. Talukdar S., Kundu S.C. A non-mulberry silk fibroin protein based 3D in vitro tumor model for evaluation of anticancer drug activity. Adv. Funct. Mater. 2012, 22:4778-4788.
135. Jiang X., Sha X., Xin H., Xu X., Gu J., Xia W., Chen S., Xie Y., Chen L., Chen Y., Fang X. Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. Biomaterials 2013, 34:2969-2979.
136. Cheng H., Kastrup C.J., Ramanathan R., Siegwart D.J., Ma M., Bogatyrev S.R., Xu Q., Whitehead K.A., Langer R., Anderson D.G. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 2010, 4:625-631.
137. Chen H.H., Chien C.C., Petibois C., Wang C.L., Chu Y.S., Lai S.F., Hua T.E., Chen Y.Y., Cai X., Kempson I.M., Hwu Y., Margaritondo G. Quantitative analysis of nanoparticle internalization in mammalian cells by high resolution X-ray microscopy. J. Nanobiotechnol. 2011, 9:14.
138. Abouzeid A.H., Torchilin V.P. The role of cell cycle in the efficiency and activity of cancer nanomedicines. Expert Opin. Drug Deliv. 2013, 10:775-786.
139. England C.G., Priest T., Zhang G., Sun X., Patel D.N., McNally L.R., van Berkel V., Gobin A.M., Frieboes H.B. Enhanced penetration into 3D cell culture using two and three layered gold nanoparticles. Int. J. Nanomedicine 2013, 8:3603-3617.
140. Godugu C., Patel A.R., Desai U., Andey T., Sams A., Singh M. AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS ONE 2013, 8.
141. Ho V.H.B., Slater N.K.H., Chen R. PH-responsive endosomolytic pseudo-peptides for drug delivery to multicellular spheroids tumour models. Biomaterials 2011, 32:2953-2958.
142. Meng W., Kallinteri P., Walker D.A., Parker T.L., Garnett M.C. Evaluation of poly (glycerol-adipate) nanoparticle uptake in an in vitro 3-D brain tumor co-culture model. Exp. Biol. Med. (Maywood) 2007, 232:1100-1108.
143. Robinson J.T., Hong G., Liang Y., Zhang B., Yaghi O.K., Dai H. In vivo fluorescence imaging in the second near-infrared window with long circulating carbon nanotubes capable of ultrahigh tumor uptake. J. Am. Chem. Soc. 2012, 134:10664-10669.
144. Takeda M., Tada H., Higuchi H., Kobayashi Y., Kobayashi M., Sakurai Y., Ishida T., Ohuchi N. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine. Breast Cancer 2008, 15:145-152.
145. Blechinger J., Bauer A.T., Torrano A.A., Gorzelanny C., Brauchle C., Schneider S.W. Uptake kinetics and nanotoxicity of silica nanoparticles are cell type dependent. Small 2013, 9:3970-3980. (3906).
146. Gibbs-Flournoy E.A., Bromberg P.A., Hofer T.P., Samet J.M., Zucker R.M. Darkfield-confocal microscopy detection of nanoscale particle internalization by human lung cells. Part. Fibre Toxicol. 2011, 8:2.
147. Heng B.C., Zhao X., Xiong S., Ng K.W., Boey F.Y., Loo J.S. Cytotoxicity of zinc oxide (ZnO) nanoparticles is influenced by cell density and culture format. Arch. Toxicol. 2011, 85:695-704.
148. Behan B.L., DeWitt D.G., Bogdanowicz D.R., Koppes A.N., Bale S.S., Thompson D.M. Single-walled carbon nanotubes alter Schwann cell behavior differentially within 2D and 3D environments. J. Biomed. Mater. Res. A 2011, 96 A:46-57.
149. Movia D., Prina-Mello A., Bazou D., Volkov Y., Giordani S. Screening the cytotoxicity of single-walled carbon nanotubes using novel 3D tissue-mimetic models. ACS Nano 2011, 5:9278-9290.
150. Jain M.P., Choi A.O., Neibert K.D., Maysinger D. Probing and preventing quantum dot-induced cytotoxicity with multimodal α-lipoic acid in multiple dimensions of the peripheral nervous system. Nanomedicine 2009, 4:277-290.
151. Lee J., Lilly G.D., Doty R.C., Podsiadlo P., Kotov N.A. In vitro toxicity testing of nanoparticles in 3D cell culture. Small 2009, 5:1213-1221.
152. Luo Y., Wang C., Hossain M., Qiao Y., Ma L., An J., Su M. Three-dimensional microtissue assay for high-throughput cytotoxicity of nanoparticles. Anal. Chem. 2012, 84:6731-6738.
153. Loessner D., Little J.P., Pettet G.J., Hutmacher D.W. A multiscale road map of cancer spheroids - incorporating experimental and mathematical modelling to understand cancer progression. J. Cell Sci. 2013, 126:2761-2771.
154. Ng K.W., Tham W., Lim T.C., Werner Hutmacher D. Assimilating cell sheets and hybrid scaffolds for dermal tissue engineering. J. Biomed. Mater. Res. A 2005, 75:425-438.
155. Bhise N.S., Ribas J., Manoharan V., Zhang Y.S., Polini A., Massa S., Dokmeci M.R., Khademhosseini A. Organ-on-a-chip platforms for studying drug delivery systems. J. Control. Release 2014, (in press). 10.1016/j.jconrel.2014.05.004.
156. Hwang C.M., Khademhosseini A., Park Y., Sun K., Lee S.H. Microfluidic chip-based fabrication of PLGA microfiber scaffolds for tissue engineering. Langmuir 2008, 24:6845-6851.
157. Mueller D., Kramer L., Hoffmann E., Klein S., Noor F. 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicol. In Vitro 2014, 28:104-112.
158. Brandenburger M., Wenzel J., Bogdan R., Richardt D., Nguemo F., Reppel M., Hescheler J., Terlau H., Dendorfer A. Organotypic slice culture from human adult ventricular myocardium. Cardiovasc. Res. 2012, 93:50-59.